Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316550 · ClinicalTrials.gov registry record · Phase 1
Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome
A Phase 1 study, sponsored by Avera Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00316550 is a Phase 1 study that was terminated before completion, run by Avera Pharmaceuticals. The registered enrollment target is 24 participants.
The verdict
NCT00316550, a Phase 1 study, was terminated before completion, sponsored by Avera Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
Interventions
- DRUG AV608
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2006-04 |
| Est. Completion | 2007-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316550
The ClinicalTrials.gov registry entry for NCT00316550 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Avera Pharmaceuticals, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AV608 is the first listed.
NCT00316550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316550 about?
NCT00316550 is a clinical study titled "Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome". The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.
What is the current status of trial NCT00316550?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2006-04. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00316550?
The interventions under investigation include: AV608 (DRUG).
Who is sponsoring clinical trial NCT00316550?
This trial is sponsored by Avera Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.